This study was heavily biased toward smoking related HNC and as we know HPV16+ has very different response with standard of care regimen.

Group A: weekly cycle cisplatin
Group B: 3 week cycle cisplatin

Cigarette smokers
Group A 25 (80%); Group B 18 (78%); Overall: 43 (78%)

Also, very low percentage had induction so another major variation at least in comparing my profile;

Neoadjuvant chemo
Group A: 8 (25%); Group B: 5 (17%); Overall: 12 (22%)

Both figures show the weekly regime offers better outcomes:
1) Predicted Survival for Patients Treated
with Weekly Cisplatin (group A) versus the Standard
Regimen (group B)
2) Predicted Time to Local Relapse (TTloR)
for Patients Treated with Weekly Cisplatin (group A)
versus the Standard Regimen (group B)

I will try to find some trail results later today but so far the weekly regimen seems fine.

Thanks
Don